Ergoteles’s Alpha Tau Medical DRTS Stock Holding History

Ergoteles’s Portfolio DRTS Stock Details DRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30,266	Closed	-$273K	–	1645
2022 Q2	$273K	Buy	30,266 +17,866	+144%	+$160K	0.01%	1154
2022 Q1	$146K	Buy	+12,400	New	+$146K	0.01%	1059

Other funds holding DRTS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's DRTS Position: Q3 2022 in Review

Ergoteles sold out of Alpha Tau Medical (DRTS) in Q3 2022, closing a stake of 30,266 shares — an estimated $273K sold.

Ergoteles first reported a position in DRTS in Q1 2022 and held it in 2 quarters. The position peaked at $273K in Q2 2022. 18 funds tracked by Wall St. Rank hold DRTS as of Q3 2022.

Ergoteles reported no remaining Alpha Tau Medical position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 30,266 Alpha Tau Medical shares in Q3 2022, an estimated $273K.
Ergoteles first reported a position in Alpha Tau Medical in Q1 2022 and held it in 2 quarters.
Ergoteles's Alpha Tau Medical position peaked at $273K in Q2 2022.
18 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.